Inhibrx Biosciences, Inc. · NASDAQ:INBX

Inhibrx Biosciences — Investor Presentation (November 2021)

39 slides from Inhibrx Biosciences's investor presentation, November 2021

  1. Slide 1: Innovation Driven, Outcomes Focused

    Innovation Driven Outcomes Focused November 2021

  2. Slide 2: Presentation disclaimer

    Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can could differ materially from the plans, intentions and expectations disclosed in the identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” forward-looking statements t

  3. Slide 3: Inhibrx at a glance

    Inhibrx at a glance VALIDATION FROM INDUSTRY LEADING PARTNERS + Experienced leadership team All platforms and programs + Proven innovation and execution developed in-house with strong patent protection + Ability to precision engineer to specific target biology + Smaller than conventional antibodies

  4. Slide 4: Four differentiated clinical programs

    Four differentiated clinical programs Rare diseases Oncology Cell death pathway Immuno-oncology INBRX-101 INBRX-109 INBRX-106 INBRX-105 AAT-Fc fusion protein Tetravalent DR5 agonist Hexavalent OX40 agonist PD-L1 x 4-1BB tetravalent + Potential for first meaningful + Single agent activity + Potential

  5. Slide 5: Why invest in Inhibrx?

    Why invest in Inhibrx? KEY FINANCIAL HIGHLIGHTS* $141.1M Cash Four differentiated clinical Potential to reach programs with value-creating financial sustainability readouts in 2H 2021/2022 with minimal dilution $25M Average per Qtr burn rate 38.9M Common stock outstanding Backed by solid institution

  6. Slide 6: INBRX-101

    AAT INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein Fc

  7. Slide 7: Alpha-1 antitrypsin deficiency (AATD)

    Alpha-1 antitrypsin deficiency (AATD) AAT Serum levels in patients receiving weekly pdAAT 60 Disease overview + AATD is an inherited orphan respiratory disease characterized by deficient levels Mean Serum AAT level (μM) of alpha-1 antitrypsin (AAT) causing loss 40 Normal AAT of lung function and dec

  8. Slide 8: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101

    Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 Potential advantages of INBRX-101 Potential to extend Goal is to maintain patients Recombinant manufacturing the dosing interval in the normal serum range provides unlimited supply from weekly to monthly of AAT and to normalize and

  9. Slide 9: Competitive comparison

    Competitive comparison 100% Applicable to all patients 15% Applicable to ~15% of patients with liver issues THERAPIES STATUS THERAPIES STATUS Aralast ARO-AAT Phase 2 Glassia DCR-A1AT Phase 2 Approved Plasma-Derived AAT Prolastin-C Zemaira Inhaled AAT Phase 2 Oral Neutrophil Alvelestat Phase 2 Elasta

  10. Slide 10: INBRX-101 initial results from Phase 1, Part 1

    INBRX-101 - Initial results from Phase 1, Part 1 PART 1 Key functional AAT levels by dose Single ascending 60 dose escalation (SAD) Complete Functional AAT levels (μM) N=24 40 Baseline AAT Max AAT N= 6 10 mg/kg Day 21 AAT N= 6 40 mg/kg 20 N= 6 80 mg/kg N= 6 120 mg/kg 0 10 40 80 120 INBRX-101 single

  11. Slide 11: INBRX-101 initial results from Phase 1, Part 2

    INBRX-101 - Initial results from Phase 1, Part 2 - 40 mg/kg PART 2 INBRX-101 Initial Results - 40 mg/kg (Q3W) Multiple ascending 40 dose escalation (MAD) Functional AAT levels (μM) 30 N=18 N= 6 40 mg/kg 20 Complete N= 6 80 mg/kg* 10 N= 6 120 mg/kg* Initiated 0 0 21 42 63 * bronchoalveolar lavage Tim

  12. Slide 12: INBRX-109

    INBRX-109 Tetravalent DR5 Agonist

  13. Slide 13: Tetravalent DR5 agonist

    Tetravalent DR5 agonist DR5: sdAb DR5: sdAb + Death receptor 5 (DR5) is a receptor DR5: sdAb DR5: sdAb for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells Fc: effector function disabled 105 kDa 13

  14. Slide 14: INBRX-109 is a best-in-class DR5 agonist

    INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) STATUS INBRX-109 Tetravalent 105 Phase II TAS-266 Tetravalent 60 Discontinued1 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 Phase I GEN10292 Dodecavalent 150 ka (2x mAbs) Discontinued IGM-8444 Decavalent3 ~950 Phase I Dulan

  15. Slide 15: Fast to market opportunity

    Fast to market opportunity Chondrosarcoma PFS from placebo-controlled studies Incidence rate of ~1 in 200,000 persons per year Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) Placebo arm PFS 2.9 months ~1,400 cases per year Therapeutic Regorafenib Control arm Placebo USA Worldw

  16. Slide 16: INBRX-109 preliminary Phase 1 data in chondrosarcoma

    INBRX-109 preliminary Phase 1 data in unresectable or metastatic conventional chondrosarcoma Best Response 3mo 4mo 6mo 9mo 12mo SD (-20%) 77wks SD (-11%) 64wks SD (-7%) 62wks PR (-61%) SD (-13%) SD (+3%) PR (-32%) SD (-4%) ** SD (-1%) ► SD (-3%) SD (-20%) ► SD (+5%) SD (+3%) * SD (-5%) * SD (+5%) SD

  17. Slide 17: INBRX-109 Phase 2 registration-enabling study design

    INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma Randomization INBRX-109 Placebo Conventional chondrosarcoma, grade 2 and 3, unresectable or metastatic N=134* N= 67 * Stratification 3 mg/kg every Until PD or toxicity by line of therapy & Grade three weeks with cross-over Initia

  18. Slide 18: Preliminary Phase 1 data in malignant pleural mesothelioma

    Preliminary Phase 1 data-malignant pleural mesothelioma, epithelioid subtype Best Response 3mo 4mo 6mo 9mo PART 3 SD (-24%) * SD (-17%) Combination SD (-12%) study PR (-100%) SD (-22%) Mesothelioma with SD (-20%) N=20 Cis-/Carboplatin sd (-12%) & Pemetrexed SD (-5%) SD (-2%) SD (+9%) H1 2022 SD (+13

  19. Slide 19: INBRX-109 on the horizon

    INBRX-109 on the horizon PART 3 FUTURE POTENTIAL OPPORTUNITIES Combination studies Solid tumors + IAP antagonists Pancreatic adenocarcinoma Hematologic tumors N=20 2nd line with FOLFIRI Ongoing + Bcl-2 inhibitors Ewing sarcoma NSCLC N=20 with Irinotecan + various combo agents Initiated Gastric and c

  20. Slide 20: INBRX-106

    INBRX-106 Hexavalent OX40 Agonist

  21. Slide 21: Hexavalent OX40 agonist

    Hexavalent OX40 agonist OX40: sdAb OX40: sdAb OX40 is a co-stimulatory receptor on activated T-cells: OX40: sdAb OX40: sdAb + Provides co-stimulation to activated T-cells + Reverses regulatory T-cell induced OX40: sdAb OX40: sdAb immune suppression + Enhances T-cell functionality + Additional benefi

  22. Slide 22: INBRX-106 is a best-in-class OX40 agonist

    INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hex- IgG1 N Ph 1 (2019) MOXR-0916 Discontinued GSK-3174998 Ph 1 (MM, 2019) BMS-986178 Ph 1 (2016) INCAGN-1949 Bi- IgG1 Y Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Discont

  23. Slide 23: INBRX-106 Phase 1 trial design

    INBRX-106 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Single agent Complete Single agent Ongoing Dose escalation Ongoing Dose expansion Planned dose escalation dose expansion with Keytruda™ with Keytruda™ N=20 N= 24 N= 13 N=80 Dose optimization study No pre-screening, all-comers N=20 PD-L1+NSCL

  24. Slide 24: INBRX-105

    INBRX-105 PD-L1 x 4-1BB Multispecific

  25. Slide 25: PD-L1 x 4-1BB multispecific

    PD-L1 x 4-1BB multispecific PD-L1: sdAb PD-L1: sdAb + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune 4-1BB: sdAb 4-1BB: sdAb cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive

  26. Slide 26: INBRX-105 is a best-in-class 4-1BB agonist

    INBRX-105 is a best-in-class 4-1BB agonist PD-L1 x 4-1BB Bispecifics CANDIDATE FORMAT 4-1BBL BLOCKING STATUS INBRX-105 Bivalent/Bivalent No Phase I Gen-1064 Monovalent/Monovalent n/a Phase II MCLA-145 Monovalent/Monovalent Yes Phase I FS222 Bivalent/Bivalent n/a Phase I PRS-343 Bivalent/Bivalent No

  27. Slide 27: INBRX-105 Phase 1 trial design

    INBRX-105 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Single agent Complete Single agent Ongoing Dose escalation Initiated Dose expansion Planned dose escalation dose expansion with Keytruda™ with Keytruda™ N=32 N= 32 N= 12 N=80 Single agent: PD-L1+ Basket No pre-screening, all-comers N=20 PD-L

  28. Slide 28: Molecular Targeted Cytokine (MTC) Platform

    Molecular Targeted Cytokine (MTC) Platform A Targeted Detuned IL-2 Platform

  29. Slide 29: Affinity differential enables directed IL-2 expansion

    Affinity differential enables directed IL-2 expansion/enhancement of specific cell types High affinity sdAb sdAb High affinity antibody targeting INHIBRX has developed sdAbs to an extensive number of antigens + T-cell or NK cell subsets + Activating/co-stimulatory receptors Fc – effector function + Inh

  30. Slide 30: INBRX-121

    INBRX-121 NKp46 Targeted Detuned IL-2

  31. Slide 31: INBRX-121 expands the NK cell population and enhances cytotoxicity

    INBRX-121 expands the NK cell population and enhances cytotoxicity NKp46 sdAb NKp46 sdAb + NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells Fc – effector function + Proprietary IL2-X engineering disabled ensures specific modulation of NK Cells without impacting

  32. Slide 32: INBRX-121 is poised to bring NK cells to the forefront of immunotherapy

    INBRX-121 is poised to bring NK cells to the forefront of immunotherapy Improved NK Activity Safety with durability Multiple paths forward INBRX-121 NK NK Single agent NK NK Activated NK cells NK NK CYTOKINES exhibit immediate NK NK NK cytotoxicity NK INBRX-121 Combination therapy ⁺ Expands NK cell

  33. Slide 33: Expands mouse NK cells and enhances cytotoxic potential

    Expands mouse NK cells and enhances their cytotoxic potential NK cell expansion NK cell activation NK cell cytolytic activity 25 5,000 20,000 Max. fold-change (relative to vehicle) 20 4,000 15,000 Granzyme B levels 15 3,000 KLRG1 levels 10,000 10 2,000 5,000 5 1,000 0 0 0 NK cells CD8 T cells Tregs

  34. Slide 34: Synergizes with approved therapeutic antibodies

    Synergizes with approved therapeutic antibodies Raji tumor growth 2,000 Vehicle 1,500 INBRX-121 Tumor Volume (mm3) 1,000 Rituxan INBRX-121 synergizes with Rituxan® INBRX-121 + Rituxan in a subcutaneous 500 Raji tumor model resulting in complete 0 tumor regression 0 7 14 21 28 35 42 Dosing Time (days

  35. Slide 35: INBRX-121 safely expands NK cells in non-human primates

    INBRX-121 safely expands NK cells in non-human primates NK cell expansion in blood after NK Expands NK cells a single dose of INBRX-121 at 1 mg/kg: NK in a dose-dependent NK NK manner (up to 12-fold) Frequency of lymphocytes NK NK NK NK that persists for more than Pre-dose Day 10 NK 21 days and can

  36. Slide 36: Expands NK cells from lymphoma patients

    Expands NK cells from Lymphoma patients IL-2 signaling in patient NK cells Patient NK cell proliferation 60 60 % pSTAT5 positive 40 40 % Ki67 positive 20 20 0 0 INBRX-121 - + - + - + - + INBRX-121 - + - + - + - + DLBCL MCL FL Healthy DLBCL MCL FL Healthy Donor Donor NK cells from Lymphoma patients e

  37. Slide 37: Expands NK cell number while enhancing cytotoxic capacity

    Expands the number of NK cells while enhancing their individual cytotoxic capacities 120 100 80 %Target celldeath Anti-hCD20-hlgG1 only INBRX-121 increases NK 60 Anti-hCD20-hlgG1 + cell-mediated killing of 40 INBRX-121 Raji cells in the presence of a Rituximab sequence 20 analog (Anti-hCD20- hIgG1).

  38. Slide 38: Near term expected clinical milestones

    Near term expected clinical milestones INBRX-105 INBRX-109 INBRX-109 INBRX-105 (PD-L1 x 41BB) (DR5) Initial (DR5) Ewing (PD-L1 x 41BB) Keytruda dose pancreatic sarcoma Keytruda dose escalation data and mesothelioma combination expansion combination study data cohort data study data Q4 2021 H1 2022 H

  39. Slide 39: Contact

    11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com

Inhibrx — Investor Presentation (November 2021) on 6ix